Rational Combination of MAP4K4 Inhibition and Immunotherapy in Pancreatic Cancer
Congressional District Code:
Biomedical Laboratory R&D
October 2020 -
FY 2021 Funding Amount:
Total Award Amount (all years):
View full abstract and other project information on NIH RePORTER Go To NIH RePORTER Excerpt:
Summary/Abstract: Pancreatic Ductal Adenocarcinoma (PDAC) remains remarkably lethal with a 5-year survival rate of less than 9%. Due to its widespread resistance to conventional therapy, PDAC is expected to be the second most common cause of cancer-related death in the United States by 2030. Oncogenic KRAS mutations are nearly uniform in PDAC, affecting over 90% of patients. The mutant KRAS is a key driver in the neoplastic phenotype, and leads to hyper-activation of KRAS, permitting for sustain...